Chemed (NYSE:CHE) announced its quarterly earnings results on Monday, October 29th. The company reported $3.07 EPS for the quarter, beating the Zacks’ consensus estimate of $2.80 by $0.27, MarketWatch Earnings reports. The business had revenue of $444.15 million during the quarter, compared to analyst estimates of $445.16 million. Chemed had a net margin of 11.73% and a return on equity of 35.13%. Chemed’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.15 EPS. Chemed updated its FY 2018 guidance to $11.80-11.90 EPS and its FY18 guidance to $11.80-11.90 EPS.
Shares of NYSE:CHE traded up $0.14 during midday trading on Thursday, reaching $299.49. The company had a trading volume of 74,826 shares, compared to its average volume of 118,924. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.11 and a current ratio of 1.14. The company has a market capitalization of $4.79 billion, a P/E ratio of 55.88, a price-to-earnings-growth ratio of 2.62 and a beta of 1.23. Chemed has a 52-week low of $234.00 and a 52-week high of $335.99.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Monday, November 12th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Thursday, November 8th. Chemed’s dividend payout ratio (DPR) is currently 22.39%.
A number of equities analysts have issued reports on CHE shares. Zacks Investment Research reaffirmed a “buy” rating and set a $342.00 price objective on shares of Chemed in a report on Monday, November 12th. Royal Bank of Canada lifted their price objective on shares of Chemed to $321.00 and gave the stock a “market perform” rating in a report on Monday, July 30th. ValuEngine downgraded shares of Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Finally, Bank of America began coverage on shares of Chemed in a report on Friday, October 12th. They set a “buy” rating and a $390.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $332.00.
In other Chemed news, VP Michael D. Witzeman sold 1,706 shares of the company’s stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $322.00, for a total transaction of $549,332.00. Following the sale, the vice president now directly owns 4,000 shares of the company’s stock, valued at $1,288,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David Patrick Williams sold 10,000 shares of the company’s stock in a transaction dated Tuesday, November 20th. The shares were sold at an average price of $302.30, for a total value of $3,023,000.00. Following the sale, the insider now owns 24,918 shares in the company, valued at $7,532,711.40. The disclosure for this sale can be found here. Insiders sold a total of 25,990 shares of company stock worth $8,017,220 over the last three months. 4.90% of the stock is owned by insiders.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.